Quest Diagnostics

DGX

Market cap $20.7B

Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.

Quest Diagnostics (DGX) remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas. It has proven itself as a cashflow and dividend grower, achieving strong margins among peers and similar competitor Labcorp, and making progress on FDA approvals.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.

Quest Diagnostics Incorporated (NYSE:DGX ) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDT Company Participants Sam Samad - Executive VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay, we're going to kick it off. I'm Tycho Peterson from the life science team at Jefferies.

SECAUCUS, N.J. , Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens.

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.